Northpond Ventures

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Eleanor Health is a provider of addiction and mental health services focused on delivering long-term recovery outcomes through a value-based care model. Founded in 2019 and headquartered in Waltham, Massachusetts, Eleanor offers comprehensive, whole-person care for mental health and substance misuse. The company operates a network of outpatient clinics and also provides virtual care as well as support in patients' homes and communities. Its services include medication-assisted treatment, evidence-based outpatient care, behavioral health services, and personalized recovery plans, all aimed at facilitating a faster recovery process for individuals suffering from substance abuse disorder.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Transition Bio, Inc. is a biotechnology company dedicated to advancing human health through the discovery, analysis, and modulation of biological condensates. Founded in 2020 and based in Cambridge, Massachusetts, with a branch in Cambridge, United Kingdom, the company has developed a hypothesis-free drug discovery and diagnostics platform known as Condensomics. This innovative platform leverages droplet microfluidic technologies and protein biophysics to study condensates with remarkable precision, providing medical practitioners with detailed molecular mappings. Transition Bio's approach is designed to unlock new opportunities for drug development, setting it apart in the biopharmaceutical landscape.

Eleanor Health is a provider of addiction and mental health services focused on delivering long-term recovery outcomes through a value-based care model. Founded in 2019 and headquartered in Waltham, Massachusetts, Eleanor offers comprehensive, whole-person care for mental health and substance misuse. The company operates a network of outpatient clinics and also provides virtual care as well as support in patients' homes and communities. Its services include medication-assisted treatment, evidence-based outpatient care, behavioral health services, and personalized recovery plans, all aimed at facilitating a faster recovery process for individuals suffering from substance abuse disorder.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

OPT Industries, founded by Jifei Ou in Cambridge, Massachusetts in 2019, specializes in digital manufacturing at the micron-scale. The company employs vertically integrated machinery, software, and design expertise to deliver precision-engineered products at high volumes with shortened lead times. Its technology enables globally-recognized brands to develop novel product concepts and bring them swiftly to commercialization.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Emulate, Inc. is a biotechnology company specializing in organs-on-chips technology that emulates human biology to enhance the understanding of diseases, medicines, chemicals, and food impacts on human health. The company develops organ-chips that replicate normal organ functions as well as various disease states, primarily targeting the lung, intestine, liver, and skin. Emulate's innovative human emulation system provides researchers with advanced in vitro models that offer more precise and detailed predictions of human responses compared to traditional experimental methods, such as cell culture or animal testing. The company serves a diverse range of markets, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic research. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. before rebranding in July 2014.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Torus Biosystems is a biotechnology company founded in 2019 and based in Cambridge, Massachusetts. It specializes in the development of a diagnostic device that facilitates DNA testing for scientific and medical research applications. The company's apparatus is designed for use across various sectors, including consumer products, food safety for humans and animals, personal care, and agriculture. By providing accessible DNA testing solutions, Torus Biosystems aims to enhance the understanding of biochemical agents in both medical and non-medical contexts.

Outcomes4me Inc. is a healthcare technology company based in Cambridge, Massachusetts, founded in 2017. It has developed an AI-driven patient empowerment platform specifically designed for cancer patients, enabling them to take a proactive approach in managing their care. The platform provides personalized, evidence-based treatment options and real-time clinical information, facilitating informed decision-making and improving patient outcomes. By connecting patients with healthcare providers and offering resources related to breast cancer treatment and clinical trials, Outcomes4me aims to democratize healthcare and promote health equity. The company is led by a team of experienced professionals from healthcare, oncology, pharmaceuticals, and technology sectors, dedicated to generating insights that enhance care and accelerate research and access to innovative treatments.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development and manufacturing of reagents for marker multiplexing detection and analysis. Founded in 2015, the company focuses on tissue imaging, diagnostics, and multiplexing to enhance research in the life sciences and biomedical fields. Ultivue's innovative technologies, including DNA-PAINT and DNA-Exchange, facilitate the collection of high-resolution microscopic images that contribute to a deeper understanding of biological processes and diseases. The company’s multiplex biomarker assays are designed for tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine. Ultivue's products are intended for fluorescent microscopy-based research and hold potential for clinical diagnostic applications.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

NanoView Biosciences is a medical technology company focused on the detection and characterization of extracellular vesicles, particularly exosomes, through its proprietary ExoView technology. Founded in 2015 and headquartered in Boston, Massachusetts, the company offers a range of products, including the ExoView R100 and ExoView Tetraspanin, as well as related kits and custom assays. NanoView's high-throughput, cost-effective analysis solutions provide life science researchers with critical insights into the biological roles of exosomes, enhancing the understanding of their potential as biomarkers for disease diagnosis, treatment, and monitoring. The company's platform is capable of analyzing nanoparticles from complex biological samples such as whole blood, serum, plasma, and urine, thereby supporting advancements in precision medicine.

Emulate, Inc. is a biotechnology company specializing in organs-on-chips technology that emulates human biology to enhance the understanding of diseases, medicines, chemicals, and food impacts on human health. The company develops organ-chips that replicate normal organ functions as well as various disease states, primarily targeting the lung, intestine, liver, and skin. Emulate's innovative human emulation system provides researchers with advanced in vitro models that offer more precise and detailed predictions of human responses compared to traditional experimental methods, such as cell culture or animal testing. The company serves a diverse range of markets, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic research. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. before rebranding in July 2014.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development and manufacturing of reagents for marker multiplexing detection and analysis. Founded in 2015, the company focuses on tissue imaging, diagnostics, and multiplexing to enhance research in the life sciences and biomedical fields. Ultivue's innovative technologies, including DNA-PAINT and DNA-Exchange, facilitate the collection of high-resolution microscopic images that contribute to a deeper understanding of biological processes and diseases. The company’s multiplex biomarker assays are designed for tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine. Ultivue's products are intended for fluorescent microscopy-based research and hold potential for clinical diagnostic applications.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

908 Devices Inc. is a Boston-based company that specializes in the development and sale of handheld and desktop measurement devices for chemical and biochemical analysis. Founded in 2012, the company leverages mass spectrometry technology to create portable tools designed for immediate application in various fields, including life sciences research, bioprocessing, industrial biotechnology, and forensics. Its product lineup includes the MX908, a battery-powered, handheld mass spectrometry device capable of rapid analysis of unknown gas, liquid, and solid materials; the Rebel, a desktop analyzer offering real-time data on bioprocess environments; and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. 908 Devices aims to provide reliable and actionable insights in challenging environments, meeting the needs of professionals who require efficient solutions for complex analytical tasks.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

NanoView Biosciences is a medical technology company focused on the detection and characterization of extracellular vesicles, particularly exosomes, through its proprietary ExoView technology. Founded in 2015 and headquartered in Boston, Massachusetts, the company offers a range of products, including the ExoView R100 and ExoView Tetraspanin, as well as related kits and custom assays. NanoView's high-throughput, cost-effective analysis solutions provide life science researchers with critical insights into the biological roles of exosomes, enhancing the understanding of their potential as biomarkers for disease diagnosis, treatment, and monitoring. The company's platform is capable of analyzing nanoparticles from complex biological samples such as whole blood, serum, plasma, and urine, thereby supporting advancements in precision medicine.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Outcomes4me Inc. is a healthcare technology company based in Cambridge, Massachusetts, founded in 2017. It has developed an AI-driven patient empowerment platform specifically designed for cancer patients, enabling them to take a proactive approach in managing their care. The platform provides personalized, evidence-based treatment options and real-time clinical information, facilitating informed decision-making and improving patient outcomes. By connecting patients with healthcare providers and offering resources related to breast cancer treatment and clinical trials, Outcomes4me aims to democratize healthcare and promote health equity. The company is led by a team of experienced professionals from healthcare, oncology, pharmaceuticals, and technology sectors, dedicated to generating insights that enhance care and accelerate research and access to innovative treatments.